

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Cost-effectiveness of Educational Interventions Targeting Living Kidney Donation

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025684
Article Type:	Protocol
Date Submitted by the Author:	31-Jul-2018
Complete List of Authors:	Redeker, Steef; Erasmus Medical Center, Medical Psychology and Psychotherapy Oppe, Mark ; EuroQol Research Foundation Visser, Martijn; Erasmus MC, Psychiatry, Section Medical Psychology and Psychotherapy Busschbach, Jan; Erasmus MC, Psychiatry, Section Medical Psychology and Psychotherapy Weimar, Willem; Erasmus MC, Internal Medicine Massey, Emma; Erasmus MC, Internal Medicine Ismail, Sohal; Erasmus MC, Psychiatry, Section Medical Psychology and Psychotherapy
Keywords:	HEALTH ECONOMICS, End stage renal failure < NEPHROLOGY, Renal transplantation < NEPHROLOGY, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

Only

Cost-effectiveness of Educational Interventions Targeting Living Kidney Donation

Authors:

Steef Redeker, MSc^a

Mark Oppe, PhD^b

Martijn Visser, MSc^a

Jan Busschbach, PhD^a

Willem Weimar, PhD^c

Emma K. Massey, PhD^c

Sohal Ismail, PhD^a

For the 'Nierteam aan Huis' consortium

Affiliations:

^a Erasmus Medical Center, Section of Medical Psychology and Psychotherapy, Department of Psychiatry, Rotterdam, The Netherlands

^b EuroQol Research Foundation, Rotterdam, The Netherlands.

^c Erasmus Medical Center, Section of Transplantation, Department of Internal Medicine, The Netherlands

Contact information corresponding author

Steef Redeker

Erasmus MC, Psychiatry, Section Medical Psychology and Psychotherapy

Postal address: PO Box 2040, 3000 CA Rotterdam, The Netherlands

Work Phone: +31 10 704 38 05; Mobile Phone: +31 6 11 88 16 65

s.redeker@erasmusmc.nl

Participants of the Nierteam aan Huis consortium:

Bemelman, F., Pant, van der, K., Zwiers, N., Fleur, W. (AMC); Wetering, van de, J., Weimar, W. Massey, E.K., Ismail, S.Y., Noord, van, M.A.A., Busschbach, J.J., Redeker, S., Berkel, van, I., Wageveld, K. (EMC); Clarisse, I., Hollander, D., Linde van de P., Dijk, van, C. (JBZ); Dorpel, van den, M. Rovers, E., Dongen, van, D., Kooij, van T., Marel, van der, T. (Maasstad Ziekenhuis); Brulez, H., Zwiers, L., Wisse, E. (OLVG West); Dooper, I., Hilbrands, L., Lobeek, M., Hopman, S. (Radboud UMC); Sanders, J., Berger, S., Waijer, J., Kisteman, M. (UMCG); Mahangoe, M., Dekker-Janssen, M., Hutten, F., Potgieter, J. (ZGT); Boonstra, C. (De Viersprong)

Trial Registration

Netherlands Trial Register, NTR6717

Keywords

Living donation, Kidney Transplantation, Cost-benefit analysis, kidney diseases, Health policy

Word count: 4155

Abstract**Introduction**

Living donor kidney transplantation (LDKT) is the optimal treatment for most patients with end-stage renal disease (ESRD). However, there are numerous patients who cannot find a living kidney donor. Randomized controlled trials have shown that home-based education for patients with ESRD and their family/friends leads to four times more LDKTs. This educational intervention is currently being implemented in eight hospitals in the Netherlands. Supervision and quality assessment are being employed to map generalizability of the randomized trial while maintaining quality. There are a number of aims of this study: (1) to conduct a cost-effectiveness analysis of the educational program and its quality assurance system; (2) to investigate the relationship between the quality of the implementation of the intervention and the outcomes knowledge, communication, and LDKT activities; and (3) to investigate policy implications.

Methods and design

Patients with ESRD who do not have a living kidney donor are eligible to receive the home-based educational intervention. This is carried out by allied-health transplantation professionals across 8 hospitals in The Netherlands. The cost-effectiveness analysis will be conducted with a Markov model. Costs data will be obtained from the literature. We will obtain the quality of life data from the patients who are approached for the educational program. Questionnaires will be used to measure the outcomes of the program. Data on LDKT activities will be obtained from medical records up to 24 months after the education. Protocol adherence measures will be assessed by a third party by means of a telephone interview with the patients and the invitees.

Ethics and dissemination

Ethical approval is obtained through all participating hospitals. Results will be disseminated through peer-reviewed publications and scientific presentations. Results of the cost-effectiveness of the educational program will also be disseminated to the Dutch National Health Care Institute.

Strengths and limitations of this study

- Working with a state-transition model involves a trade-off between feasibility and transparency of the model and the level of details of real life conditions.
- We do not have a control group in the implementation study, we will use the reported effectiveness of a randomized controlled trial.
- By making a dynamic state-transition model, we can model the prevalence and incidence of patients with end-stage renal disease, and consequently the capacity for the facility needs which has not been done before.
- We have a high quality data at our disposal.

Introduction

Living donor kidney transplantation (LDKT) is the optimal treatment for most patients with end-stage renal disease (ESRD) in terms of Quality Adjusted Life Years (QALYs), survival and cost-effectiveness [1]. However, there is a significant number of patients who cannot find a living kidney donor and many patients first undergo dialysis before transplantation with a living donor kidney. Interventions are needed to improve access to LDKT.

Research has shown that knowledge of renal replacement therapies (RRT) and communication between patients and their social circle play an important role in the access to LDKT [2]. Studies have shown that a home-based interventional program had positive effects for patients with ESRD [3-5]. In our transplant center in Rotterdam, the Netherlands, we have conducted two studies on this home-based educational approach: one randomized controlled trial (RCT) and one cross-over study. The RCT among 163 patients on dialysis showed significant increases in knowledge and communication regarding LDKT among the patients in the experimental arm who received the home-based education. Furthermore, there were significantly more actual LDKTs in the experimental group compared to the control group (17 vs 4, $p=0.003$) [3].

The cross-over trial was aimed at patients who had not previously undergone RRT and who were eligible for transplantation. In the first phase, the experimental arm received the home-based education while the control group waited. In the second phase, the control group also received the education. This study also showed that there was a statistically significant increase

1
2
3 in knowledge and communication regarding RRT among patients and invitees after receiving the
4 home-based education. Of the 80 participants, 49 underwent RRT during the two year follow-up.
5 Of these, 34 underwent a living donor kidney transplantation, of which 22 were pre-emptive [4].
6
7

8 Given these positive results, a home-based educational program for ESRD patients and
9 their social network is currently being implemented in four regions in The Netherlands. Per
10 region, a local hospital and a university transplant hospital are implementing the program. The
11 local hospitals will target pre-dialysis patients, while the university hospitals will target both pre-
12 dialysis and dialysis patients. The educators organize the intervention in such a way that they
13 will do ‘whatever it takes’, in line with one of the basic principles of multisystem therapy (MST),
14 to make this event as patient-tailored as possible. Supervision and quality assessment were
15 employed to map the generalizability of previous research. The first aim is to evaluate the cost-
16 effectiveness of the education to support continued implementation. In this article, we present the
17 study protocol of a cost-effectiveness analysis of the educational program and its quality
18 assurance system. The patient population, the standard care, the educations and the setting differ
19 per hospital. Therefore, our second objective is to investigate the relationship between the quality
20 of the implementation of the program, as measured by protocol adherence, and outcome.
21 Outcome is defined in terms of knowledge, communication, and LDKT activities.
22
23
24
25
26
27
28
29
30
31
32
33

34 **Hypotheses**

35
36 Previous research has provided convincing evidence that transplantation cost less, gives a
37 better survival and a higher quality of life compared to dialysis [6-8]. We therefore hypothesize
38 that the relatively small incremental costs of the home-based educational program, through
39 which the number of transplantations will increase, should be cost-effective. Since it is desirable
40 that in the future all waiting list patients can benefit from the effects of the home-based
41 intervention, this program should be part of standard care. Hence, a solid basis of the cost-
42 effectiveness of that educational program is warranted.
43
44
45
46
47

48 The second hypothesis is that if healthcare providers show a high protocol adherence
49 more positive intervention effects will occur. These effects include an increase of knowledge of
50 renal disease and the treatment options, an increase in communication with family/friends about
51 renal replacement therapies, an increase of living kidney donation activities, and an increase of
52
53
54
55
56
57
58
59
60

1
2
3 QALYs. If that relation between protocol adherence and effects is shown, a quality assurance
4 system should be an inseparable part of the educational program.

5
6 The third hypothesis is that a full implementation of the educational program leads to
7 policy implications regarding care for patients with ESRD. Full implementation may affect the
8 need for dialysis centers and transplantation facilities. By modelling the prevalence we can
9 estimate the need for allocating the health care budget. We aim to present the outcomes of the
10 model in a budget impact analysis (BIA).

11
12 Thus, the main aim of this article is to present the implementation plan, to discuss the
13 cost-effectiveness analysis and the quality assurance of the home-based educational program
14 which currently being implemented in The Netherlands. Additionally, potential policy
15 implications of our hypotheses are discussed in this article.

16 17 18 19 20 21 22 23 **Methods and Design**

24 25 **Participants and procedure**

26
27 The implementation study is being conducted in the following regions of the Netherlands:
28 Rotterdam, Amsterdam, Nijmegen and Groningen. An estimate of the potential candidates for
29 this implementation is about 50 patients per year per university center and 20 patients per local
30 hospital. The implementation study will take two years.

31
32 The home-based educational program is currently being implemented in eight hospitals in
33 the Netherlands; four university transplant hospitals and four local hospitals. Local hospitals
34 were included to reach those patients who are yet to start renal replacement therapy and in this
35 setting, this is the target population. In these hospitals there is a large dialysis unit but no
36 transplants are conducted. The four university hospitals incorporate both a dialysis unit and a
37 transplant center, therefore in this setting both pre-dialysis and dialysis patients are the target
38 population.

39
40 If patients have not been able to find living donor candidates in their social network, they
41 will be asked whether they and their social network wish to receive home-based education from
42 health-care educators. The nephrologist explains to the patients that the educators will provide
43 information about renal diseases and the different types of RRT. Furthermore, the educators can
44 help to discuss the possibilities of living donation within the social network of the patient. If the
45 patient consents to the intervention in consultation with his/her nephrologist, the health-care

1
2
3 educators contact the patient to make an appointment for the first home session. After
4 completion of the program an evaluation consultation is planned with the nephrologist.
5
6
7

8 **Patient and Public Involvement statement**

9
10 Patients were involved in the design of the educational program. When designing the
11 intervention we anchored the patient participation in the project approach by relying on the
12 results of focus groups in fifty patients from the intended target group. Their opinion was sought
13 regarding two methods described in the literature of additional information/coaching: 1) an
14 additional telephone consultation by the transplant doctor and 2) home education where family
15 and friends are invited to receive knowledge about RRT. 88% of the participants favoured the
16 home education over the telephone consultations [9]. Patients were not involved in the design of
17 the cost-effectiveness study.
18
19
20
21
22
23
24
25

26 **The intervention: home-based education**

27 The intervention consists of two sessions at the patient's home. In the first session the
28 goals of the educational program will be discussed and the home-based educational meeting will
29 be prepared. The educators will make an inventory of individuals in the patient's social network
30 using a socio-gram. This helps open the discussion on who to invite for the second session, the
31 home-based educational meeting.
32
33
34
35

36 In the second session the education takes place. The educators organize this session in
37 such a way that they will do 'whatever it takes', in line with one of the basic principles of
38 multisystem therapy (MST), to make this event as patient-tailored as possible. The primary goal
39 of this intervention is educational, therefore, it is not necessary that all the invitees are or become
40 potential donors. A more detailed description can be found in a published protocol manuscript
41 [10].
42
43
44
45
46
47

48 **Measures**

49 Knowledge and communication will be evaluated through questionnaires for all patients
50 and for at least one relative/friend in attendance at the home-based educational session. The
51 knowledge about renal disease and renal replacement therapies is measured through a validated
52 knowledge questionnaire R3K-T. This 21-item knowledge questionnaire has been developed
53
54
55
56
57
58
59
60

1
2
3 specifically for kidney disease, and has good psychometric properties [11]. Answer categories
4 are multiple choice and the number of correct answers are summed. The 3-item communication
5 questionnaire can be answered on a scale from 1 (completely disagree) to 5 (completely agree).
6
7 An example item is ‘I can talk about renal replacement therapies with my loved ones’. Finally
8 we will assess patients’ and invitees’ attitude towards RRT through a 9-item questionnaire. This
9
10 questionnaire can also be answered on a scale from 1 (completely disagree) to 5 (completely
11 agree). An item example is ‘I am afraid donation will harm the health of the donor’. The
12
13 administration of questionnaires will take place at two occasions 1) prior to the education either
14 during an outpatient visit after signing the ‘informed consent’ or during the first session; and 2)
15 shortly after the second session.
16
17
18
19

20 *Protocol adherence measures:* After every completed home intervention an independent
21 telephone evaluation is conducted with the patient and a relative/friend who is involved in the
22 education program, to measure the degree of protocol adherence of the educators. The
23 independence is guaranteed through an independent party, specialized in treatment adherence
24 measurement (www.Praktikon.nl). Protocol adherence in this implementation stands for the
25 extent to which the different teams carry out the educational program as described in the
26 protocol. Measurement is done with an adaptation of the ‘Treatment Adherence Measures’
27 (TAM) questionnaire [12]. TAM is scored on a 0-1 scale, where 1 stands for complete protocol
28 adherence. The results of the TAM can not only be used for research purposes, but will also be
29 used to give the educators feedback on the quality of their interventions during the
30 implementation phase.
31
32
33
34
35
36
37
38
39
40

41 **Cost-Effectiveness**

42
43 *Costs:* The latest published research on costs of dialysis and transplantation in The
44 Netherlands dates back from the late 1990s [6]. Currently, research on costs of dialysis and
45 transplantation is in its final phase. We will use that forthcoming data (De Wit, personal
46 communication). This cost data is of high quality, as it is based on the national database of
47 insurance companies from 2014, which consists of records from 99% of all Dutch citizens. Costs
48 calculations will include costs of dialysis modality, dialysis access, transplant procedure, other
49 hospital costs, primary care costs, mental health care, medication outside the hospital, medical
50 devices, health care abroad, transport, and other costs. Health care costs for transplantation,
51
52
53
54
55
56
57
58
59
60

1
2
3 include preparatory research, transplant operation, guidance, after care, donor expenses, dialysis
4 procedure, other hospital costs, primary care, mental health care, medication outside hospital,
5 medical devices, health care abroad, transportation and other costs. These include all the health
6 care costs associated with RRT. Since it is preferred that cost-effectiveness analysis are
7 conducted from a societal perspective, we also aim to calculate the productivity costs [13]. The
8 costs of the home-based intervention and the quality assurance will be estimated on the basis of
9 the current practice in the implementation.

10
11
12
13
14
15 *Effects:* In health economics the effects of interventions under evaluation are preferably
16 expressed in QALYs [13]. Research on QALYs of different dialysis modalities are widespread
17 [7, 14, 15], but instruments and patient background variables vary. Therefore, we are currently in
18 the process of collecting quality of life data from both pre-dialysis patients and dialysis patients,
19 through the EQ-5D-5L, the quality of life instrument recommended in the Dutch guidelines for
20 health economics [16]. Moreover, we will also collect quality of life data of the patients who
21 received the intervention.

22
23
24
25
26
27 *Markov Model:* To assess the cost-effectiveness of the implementation of the home-based
28 educational program, we will build a 'Markov simulation model'. This model will assess the
29 costs and effects of ESRD treatments as it simulates the course of treatment and disease of the
30 patients. The model will have a similar structure as an earlier published model on this population
31 [6], with some important updates and improvements. Unlike that Markov model, which used
32 multivariate and univariate sensitivity analyses [6], our model will include probabilistic
33 sensitivity analysis using Monte Carlo simulation. Consequently, uncertainty of all values are
34 considered simultaneously, and the uncertainty in each parameter is assumed to possess a
35 probability distribution [17]. By using probabilistic sensitivity analyses we follow current
36 guidelines in health economics [16, 18, 19]. A Markov modelling technique is applicable
37 because the decision problem involves risk that is continuous over time, the timing of events is
38 important, and event may happen more than once [20]. Within a Markov simulation, the time
39 horizon of the study is divided into a number of discrete time-periods, the so-called Markov
40 cycles. A Markov process is based on the idea that patients are always in a certain disease state
41 and that they can change between disease states once during each cycle. By assigning effects to
42 each disease state and keeping track of the time patients remained in each disease state, long-
43 term effects can be calculated.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
Model description: A simplified graphic representation of the Markov model showing only the treatment categories, rather than all the individual Markov states is represented in figure 1. Patients continuously enter the model (inflow) at the start of the cycle and can start on Hemodialysis, Peritoneal dialysis, or Transplantation. From there they can move between these treatment modalities. Since the incidence of kidney failure is increasing, we will also model this in the cost-effectiveness analysis. This will be calculated through the database of *Nefrovisie*, a large national database with records of ESRD patients. As stated before, the model will include probabilistic analysis using Monte Carlo simulation. This means that not only mean numbers of patients per year per treatment modality will be estimated, but also the uncertainty surrounding those mean number of patients, 95% confidence intervals will be estimated with bootstrapping. This is a non-parametric technique in which the model parameters are estimated a large number of times. Consequently, all model parameters (e.g. the transition probabilities) will be included in the model as distributions rather than point estimates.

26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
Markov States: The Markov states are based on the treatments currently available in The Netherlands. These are: Full Care Centre Hemodialysis, Limited Care Centre Hemodialysis, Home Hemodialysis, Continuous Ambulatory Peritoneal Dialysis, Continuous Cyclic Peritoneal Dialysis, Deceased Donor Kidney Transplantation, and Living Donor Kidney Transplantation. Since transition probabilities and costs may differ over time, i.e. a patient who is in his second year of hemodialysis has a different mortality chance than a patient who just started with hemodialysis, we will define separate Markov states for the 1st year of treatment and subsequent years of treatment with a specific modality. Incident patients that enter the model and prevalent patients that switch between treatment modalities are assigned to the 1st year Markov states, whereas patients that spend more than one year in any health state are transferred to the subsequent years of that same treatment modality.

45
46
47
48
49
50
Outcomes: The outcome of the implementation will be compared with the baseline situation; the situation before this program was implemented. A critical assumption will be the extrapolation of the effects after the 2 years.

51 52 **Quality Assurance**

53
54
55
56
57
58
59
60
This study has also implemented a central quality assurance. We hypothesize that the effectiveness is moderated by the protocol adherence of the team of healthcare professionals. In

1
2
3 the implementation study, it might be possible that there are differences in the way teams and
4 centers adhere to the protocol. A part of the quality assurance is a training that all professionals
5 that conduct the home interventions must take part in. During this training, issues are discussed
6 such as: how to convey uniform and complete information to the patient, how to behave during
7 the home visits, how to create an alignment of the goals of the home visit with the patients, how
8 to assist the patient in inviting friends and relatives, how to deal with emotional moments, how to
9 discuss delicate topic with respect to individual feelings and opinions and finally, how to ensure
10 no detrimental psychosocial effects of the education occur for the patients and his/her
11 family/friends. All these aspects can be executed in different ways by the educators. A supervisor
12 will evaluate the home visits with each functional team separately every six weeks and discuss
13 difficult cases. Furthermore, the supervisor will bring together all educators for a so-called
14 intervision meeting every three months. These intervision sessions are meant to discuss the home
15 visits with each other in order to learn from each other and to keep the procedures similar.
16
17
18
19
20
21
22
23
24
25
26
27
28

29 Discussion

30
31 We presented a protocol for assessing the cost-effectiveness of our home-based
32 educational program and its generalizability. The implementation of the educational program
33 might both benefit patients and society.
34
35

36 *Cost-effectiveness:* If indeed our hypotheses are confirmed, and the home-based
37 educational program is cost-effective, then there are convincing arguments to make the program
38 standard care in The Netherlands. Health insurers already expressed their interest in the program;
39 this implementation study is supported by *Zorgverzekeraars Nederland* (Health insurers The
40 Netherlands), which is the ‘umbrella organization’ of all health insurers in The Netherlands.
41 Additionally, the Dutch Kidney Foundation supports the program and contributed through three
42 grants in the developmental phases of the home-based educational program. The Dutch Kidney
43 Foundation is a non-profit organization which subsidizes research and innovation in nephrology
44 and renal transplantation care. Indeed, the health insurance companies have good reason to be
45 interested, as dialysis is costly. In The Netherlands, 1% of the total healthcare budget is spent on
46 ESRD patients, who only constitute 0.0006% of the population [21, 22]. Furthermore,
47 transplantation is associated with higher quality of life for ESRD patients compared to dialysis
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 treatment. It is therefore valuable, from both patient and societal perspective, to conduct a
4 complete and extensive cost-effective analysis and consequently to follow up those results in
5 terms of policy.
6
7

8 *Quality System:* Protocol adherence may be of importance to guarantee the effects of the
9 home-based education. First, we expect a positive relation of adherence with outcome in terms of
10 the quality of the decisions reached and the number of transplantations. Second, any problems or
11 regrets of donors and/or patients can only be justified if the evidence based protocol was
12 followed. The protocol has also been developed after thorough ethical consideration (23), which
13 justified all characteristics of the program. It can therefore be argued that health insurance make
14 reimbursement indispensable of the degree of protocol adherence of healthcare suppliers.
15 Moreover, they should facilitate the quality assurance over the interventions and ensure that the
16 quality of the interventions is independent of the healthcare suppliers.
17
18
19
20
21
22
23

24 *Limitations:* Investigating the (cost-)effectiveness of the home-based educational program
25 has its limitations. In health economic modelling, there is always a trade-off between the
26 feasibility and transparency of the cost-effectiveness model and the level of details of real life
27 conditions as represented in the model. The more details, the more the model resembles real life,
28 but the down side is that data should be available at that same level of detail and that the model
29 becomes too complex in its feasibility. An example is that we assume that the mortality on
30 dialysis is the same in the second and following years on dialysis. Hence, we know from
31 literature that the mortality chance changes, but the data in later years is scarce and again the
32 model would become more complex, as more ‘tunnels states’ have to be introduced. We expect
33 that this trade-off will be most prominent in the transition changes between health states. We
34 expect less obvious trade-offs for costs and utility assessment, as we have sufficient data for
35 those variables.
36
37
38
39
40
41
42
43
44

45 *Cooperation.* This investigation is a cooperation between many parties, who all have
46 expressed their support. Obviously, it is possible that this support can be withdrawn for several
47 reasons. For instance, we depend on data from a large national database with records of patient
48 with ESRD (*Nefrovisie*). Hence, much efforts are and will be put in preserving relationships and
49 communication in order to maximize fair successful implementation chances for the program.
50
51
52

53 *Ethical considerations.* Another challenge that we face, is the ethical consideration of
54 promoting living kidney donation through a home-based intervention. Previous studies on the
55
56
57
58
59
60

1
2
3 ethics of this argued that such promotion is justified, only when the conditions are met, such as
4 1) participation must be completely voluntary throughout the intervention, 2) no undue pressure
5 should be put on the participants, 3) the education is neutral and non-directive and 4) the purpose
6 and the procedure should be clear to all participants [23, 24]. That does not mean there are no
7 negative consequence whatsoever, but it does mean that the positive outcomes outweigh the
8 negative. It could well be that a patient and/or a donor may regret the decision to have
9 undertaken a transplantation with a kidney of a living donor, and that the donor and/or patient, in
10 hindsight, may have felt undue pressure to donate a kidney. Adherence to the protocol will
11 minimize these potential negative effects. However, it is possible that regret or pressure could
12 lead to negative publicity for the program. That is a risk since such negative publicity could
13 impede the chances of implementing the program as standard care [25]. Especially considering
14 that deceased organ donation is currently subject to controversy in The Netherlands since the
15 government and parliament are currently debating a new donor law. This proposed law is an opt-
16 out system entailing a positive ‘no-objection’ deceased donor organ donor registration as a
17 default for all Dutch citizens [26]. Given this potential harm due to negative publicity it is crucial
18 to have 1) a protocol which is justifiable from a medical ethical perspective, 2) widespread
19 support from the various organizations involved and 3) a high quality in terms of protocol
20 adherence and trained adequate educators. If these conditions are met, the quality of the process
21 then justify its outcome, which is a subtle trade-off between positive and negative outcomes.
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 *Implementation.* Another challenge is the generalizability of the results of the previous
37 effect study on home-based interventions done in Rotterdam. The randomized controlled trial in
38 the Rotterdam transplant area has shown that the home-based educational program leads up to
39 four times more LDKTs. The trial took place at the academic transplant center (Erasmus Medical
40 Center in Rotterdam) where extensive efforts were already undertaken as part of the standard
41 care to promote LDKTs [3, 27]. It is possible that in other transplant areas in The Netherlands,
42 with less experience regarding promoting LDKT, effectiveness in terms of amount of LDKTs
43 may differ. On one hand this more cautious attitude may lead to lower results than in the
44 Rotterdam transplant area. Hence, organizational conditions within those transplant centers may
45 not optimally facilitate the favorable results of the interventions. On the other hand, if the
46 number of LDKT was lower than in the Rotterdam area, and the uptake of the intervention is
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 high, the effect could even be higher than in the Rotterdam area. This is due to a higher effect
4 potential in those centers where living donation was not promoted as actively.
5

6 *Learning curve.* As with all new programs, educators will inherently experience a
7 learning curve during the first part of the implementation, which could influence the
8 effectiveness of the program. For instance, the goal of 50 patients per year per academic
9 transplant center and the goal of 20 patients per regional hospital may not be reached. Regular
10 supervision, (on the job) training and peer-to-peer coaching may help to overcome this, but a
11 learning curve is unavoidable.
12
13
14
15

16 *Policy implications:* One of the main pillars of an efficient health care system is the
17 ability to provide effective care to patients when needed. It is therefore necessary to have
18 information on the effectiveness of the interventions and their cost to convince policy makers to
19 reimburse the treatment. If the analysis confirms the effectiveness as well as the cost-
20 effectiveness of the home-based educational program, we recommend that this intervention
21 should be part of standard-care.
22
23
24
25
26

27 If the home-based educational interventions would become standard-care, this could have
28 several implications. First, it can be expected that patients who are unable to find a living donor
29 will nevertheless profit from an increase number of living kidney donations, as the demand for
30 deceased donor kidneys drops. In other words, the increase in living donation will further lower
31 the waiting list for deceased donor donation as well and thereby increase the chance of a
32 deceased donor donation for those patients without a living donor increases.
33
34
35
36
37

38 Second, the composition of the population of patients with ESRD may change. For
39 instance, it can be expected that the proportion of patients on dialysis will drop and patients with
40 a life sustaining transplanted kidney will increase. This might have an influence on the demand
41 for dialysis centers and the need for transplantation facilities. We, therefore, aim to incorporate
42 this in a so-called dynamic model to estimate the prevalence over time. When modelling the
43 prevalence, we could make estimates of the need for dialysis centers and transplantations
44 facilities. However, modelling the facility is surrounded by uncertainty. For instance, dialysis
45 centers may have financial incentives to fulfill dialysis capacity. If this would be the case, there
46 will be no monetary benefits for society by increasing the transplants facilities if the proportion
47 of dialysis capacity remains the same. This would mean that there will only be an increase in the
48 average quality of life of ESRD-patients.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Finally, a cost-effectiveness analysis only might not be sufficient to set policy change in
4 motion. Therefore, we anticipate that a policy recommendation accompanied with a BIA will
5 also be required. A BIA addresses the expected changes in the expenditure of a health care
6 system after the adoption of a new intervention. It can also be used for budget and resource
7 planning [28, 29].
8
9

10
11
12 *Conclusion:* If our hypotheses are confirmed, we hope by presenting an extensive cost-
13 effectiveness analysis, a BIA, and a policy recommendation that policy change will be set in
14 motion, which again would benefit both ESRD-patients and society.
15
16
17
18
19
20
21
22
23

24 **Declarations**

25 **Abbreviations**

26 BIA: Budget Impact Analysis; ESRD: End-Stage Renal Disease; LDKT: Living Donor Kidney
27 Transplantation; RCT: Randomized Controlled Trial; RRT: Renal Replacement Therapies; QALY:
28 Quality Adjusted Life Years; TAM; Treatment Adherence Measures.
29
30

31 **Acknowledgements**

32 All authors express their gratitude to the participating hospitals, the educators and their supervisors.
33

34 **Funding**

35 The research is funded by the Dutch Kidney Foundation. The implementation is supported by Dutch
36 Health Insurers.
37
38

39 **Availability of data and materials**

40 Not applicable.
41
42

43 **Author contributions**

44 SR drafted the manuscript. MO, MV, JB, WW, EM, SI provided significant critical intellectual
45 contributions. All authors reviewed and approved the final version of this manuscript and agrees to be
46 accountable for all aspects of this work.
47
48

49 **Consent for publication**

50 Not applicable.
51
52

53 **Competing interests**

54 All authors have no competing interests to report.
55
56
57
58
59
60

References

1. Mahillo B, Carmona M, Alvarez M, White S, Noel L, Matesanz R: **2009 global data in organ donation and transplantation: activities, laws, and organization.** *Transplantation* 2011, **92**(10):1069-1074.
2. Kranenburg LW, Zuidema WC, Weimar W, Hilhorst MT, IJzermans JN, Passchier J, Busschbach JJ: **Psychological barriers for living kidney donation: how to inform the potential donors.** *Transplantation* 2007, **84**:965-971.
3. Ismail SY, Luchtenburg AE, Timman R, Zuidema WC, Boonstra C, Weimar W, Busschbach JJ, Massey EK: **Home-based family intervention increases knowledge, communication and living donation rates: a randomized controlled trial.** *Am J Transplant* 2014, **14**(8):1862-1869.
4. Massey EK, Smak Gregoor PJH, Nette RW, van den Dorpel MA, van Kooij A, Zietse R, Zuidema WC, Timman R, Busschbach JJ, Weimar W: **Early home-based group education to support informed decision-making among patients with end-stage renal disease: a multi-centre randomized controlled trial.** *Nephrol Dial Transplant* 2016, **31**:823-830.
5. Rodrigue JR, Cornell DL, Lin JK, Kaplan B, Howard RJ: **Increasing live donor kidney transplantation: a randomized controlled trial of a home-based educational intervention.** *Am J Transplant* 2007, **7**(2):394-401.
6. de Wit GA, H. RP, de Charro FT: **Economic evaluation of end stage renal disease treatment.** *Health policy* 1998, **44**(3):215-232.
7. Wyld M, Morton RL, Hayen A, Howard K, Webster AC: **A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments.** *PLoS Med* 2012, **9**(9):e1001307.
8. Liem YS, Bosch JL, Hunink MG: **Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis.** *Value Health* 2008, **11**(4):733-741.
9. Ismail SY, Claassens L, Luchtenburg AE, Roodnat JJ, Zuidema WC, Weimar W, Busschbach JJ, Massey EK: **Living donor kidney transplantation among ethnic minorities in the Netherlands: a model for breaking the hurdles.** *Patient Educ Couns* 2013, **90**(1):118-124.
10. Ismail SY, Luchtenburg AE, Zuidema WC, Boonstra C, Weimar W, Massey EK, Busschbach JJ: **Multisystemic engagement & nephrology based educational intervention: a randomized controlled trial protocol on the kidney team at home-study.** *BMC Nephrology* 2012, **13**:62-70.
11. Ismail SY, Timmerman L, Timman R, Luchtenburg AE, Smak Gregoor PJH, Nette RW, van den Dorpel MA, Zuidema WC, Weimar W, Massey EK *et al*: **A psychometric analysis of Rotterdam Renal Replacement Knowledge-Test (R3K-T) using item response theory.** *Transplant International* 2013, **26**:1164-1172.

12. Chapman JE, Sheidow AJ, Henggeler SW, Halliday-Boykins C, Cunningham PB: **Developing a Measure of Therapist Adherence to Contingency Management: An Application of the Many-Facet Rasch Model.** *J Child Adolesc Subst Abuse* 2008, **17**(3):47-68.
13. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW: **Methods for the Economic Evaluation of Health Care Programmes.** Oxford: Oxford University; 2015.
14. Harris A, Cooper BA, Li JJ, Bulfone L, Branley P, Collins JF, Craig JC, Fraenkel MB, Johnson DW, Kesselhut J *et al*: **Cost-effectiveness of initiating dialysis early: a randomized controlled trial.** *Am J Kidney Dis* 2011, **57**(5):707-715.
15. Wu AW, Fink NE, Marsh-Manzi JV, Meyer KB, Finkelstein FO, Chapman MM, Powe NR: **Changes in quality of life during hemodialysis and peritoneal dialysis treatment: generic and disease specific measures.** *J Am Soc Nephrol* 2004, **15**(3):743-753.
16. Nederland Z: **Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg.** In. Diemen: Zorginstituut Nederland; 2016.
17. Doubilet P, Begg CB, Weinstein MC, Braun P, J. MB: **Probabilistic Sensitivity Analysis Using Monte Carlo Simulation.** *Med Decis Making* 1985, **5**(2):157-177.
18. Briggs AH: **Handling uncertainty in cost-effectiveness models.** *Pharmacoeconomics* 2000, **17**(5):479-500.
19. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ: **Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophage reflux disease.** *Med Decis Making* 2002, **22**:290-308.
20. Sonnenberg FA, Beck JR: **Markov Models in Medical Decision Making: A Practical Guide.** *Med Decis Making* 1993, **13**:322-338.
21. **Ranglijst ziekten op basis van zorgkosten**
[<https://www.volksgezondheidenzorg.info/ranglijst/ranglijst-ziekten-op-basis-van-zorgkosten>]
22. **Feiten en cijfers over behandeling nierfalen**
[<https://www.nierstichting.nl/leven-met-een-nierziekte/feiten-en-cijfers/>]
23. Hilhorst MT, Kranenburg LW, Busschbach JJ: **Should health care professionals encourage living kidney donation.** *Medicine, Health Care and Philosophy* 2006, **10**:81-90.
24. Massey EK, Hilhorst MT, Nette RW, Smak Gregoor PJH, van den Dorpel MA, van Kooij A, Zuidema WC, Zietse R, Busschbach JJ, Weimar W: **Justification for a home-based education programme for kidney patients and their social network prior to initiation of renal replacement therapy.** *J Med Ethics* 2011, **37**:677-681.
25. Birkland TA: **Focusing Events, Mobilization, and Agenda Setting.** *Journal of Public Policy* 1998, **18**(1):53-74.


- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
26. Eleftheriou-Smith L: **Organ Donation set to become automatic for Dutch people unless they opt out.** In: *Independent*. 2016.
 27. Roodnat JI, Kal-van Gestel JA, Zuidema W, van Noord MA, van de Wetering J, JN IJ, Weimar W: **Successful expansion of the living donor pool by alternative living donation programs.** *Am J Transplant* 2009, **9**(9):2150-2156.
 28. Niezen MG, de Bont A, Busschbach JJ, Cohen JP, Stolk EA: **Finding legitimacy for the role of budget impact in drug reimbursement decisions.** *Int J Technol Assess Health Care* 2009, **25**(1):49-55.
 29. Sullivan SD, Mauskopf JA, Augustovski F, Caro JJ, Lee KM, Minchin M, Orlewska E, Penna P, Rodriguez Barrios J-M, Wen-Yi S: **Budget Impact Analysis - Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.** *Value in Health* 2014, **17**:5-14.

Figure legends

28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: A simplified graphic representation of the Markov Model with the different health states and the transition possibilities between the health states.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



A simplified graphic representation of the Markov Model with the different health states and the transition possibilities between the health states.

234x151mm (300 x 300 DPI)

BMJ Open

Cost-effectiveness of a home-based group educational programme on renal replacement therapies: a Study Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025684.R1
Article Type:	Protocol
Date Submitted by the Author:	06-Nov-2018
Complete List of Authors:	Redeker, Steef; Erasmus MC, Psychiatry, Section Medical Psychology and Psychotherapy Oppe, Mark ; EuroQol Research Foundation Visser, Martijn; Erasmus MC, Psychiatry, Section Medical Psychology and Psychotherapy Busschbach, Jan; Erasmus MC, Psychiatry, Section Medical Psychology and Psychotherapy Weimar, Willem; Erasmus MC, Internal Medicine Massey, Emma; Erasmus MC, Internal Medicine Ismail, Sohal; Erasmus MC, Psychiatry, Section Medical Psychology and Psychotherapy
Primary Subject Heading:	Health economics
Secondary Subject Heading:	Health policy
Keywords:	HEALTH ECONOMICS, End stage renal failure < NEPHROLOGY, Renal transplantation < NEPHROLOGY, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

Cost-effectiveness of a home-based group educational programme on renal replacement therapies: a Study Protocol

Authors:

Steef Redeker, MSc^a

Mark Oppe, PhD^b

Martijn Visser, MSc^a

Jan Busschbach, PhD^a

Willem Weimar, PhD^c

Emma K. Massey, PhD^c

Sohal Ismail, PhD^a

For the 'Nierteam aan Huis' consortium

Affiliations:

^a Erasmus MC, University Medical Center Rotterdam, Department of Psychiatry, The Netherlands

^b EuroQol Research Foundation, Rotterdam, The Netherlands.

^c Erasmus MC, University Medical Center Rotterdam, Department of Internal Medicine, The Netherlands

Contact information corresponding author

Steef Redeker

Erasmus MC, Psychiatry, Section Medical Psychology and Psychotherapy

Postal address: PO Box 2040, 3000 CA Rotterdam, The Netherlands

Work Phone: +31 10 704 38 05; Mobile Phone: +31 6 11 88 16 65

s.redeker@erasmusmc.nl

Participants of the Nierteam aan Huis consortium:

Bemelman, F., Pant, van der, K., Zwiers, N., Van Milgen-Adriaens, M. (AMC); Wetering, van de, J., Weimar, W. Massey, E.K., Ismail, S.Y., Noord, van, M.A.A., Busschbach, J.J., Redeker, S., Jansen, D., Wageveld, K. (EMC); Clarisse, I., Hollander, D., Linde van de P., Dijk, van, C. (JBZ); Dorpel, van den, M. Rovers, E., Dongen, van, D., Kooij, van T., Marel, van der, T. (Maasstad Ziekenhuis); Brulez, H., Zwiers, L., Wisse, E. (OLVG West); Dooper, I., Hilbrands, L., Lobeek, M., Hopman, S. (Radboud UMC); Sanders, J., Berger, S., Waijer, J., Kisteman, M., Van der Laan, J. (UMCG); Mahangoe, M., Dekker-Janssen, M., Hutten, F., Potgieter, J. (ZGT); Boonstra, C. (De Viersprong)

Trial Registration

Netherlands Trial Register, NTR6717

Keywords

Living donation, Kidney Transplantation, Cost-benefit analysis, kidney diseases, Health policy

Word count: 4155

Abstract**Introduction**

Living donor kidney transplantation (LDKT) is the optimal treatment for most patients with end-stage renal disease (ESRD). However, there are numerous patients who cannot find a living kidney donor. Randomized controlled trials have shown that home-based education for patients with ESRD and their family/friends leads to four times more LDKTs. This educational intervention is currently being implemented in eight hospitals in the Netherlands. Supervision and quality assessment are being employed to maintain the quality of the intervention. In this study we aim to: (1) conduct a cost-effectiveness analysis of the educational programme and its quality assurance system; (2) investigate the relationship between the quality of the implementation of the intervention and the outcomes knowledge, communication, and LDKT activities; and (3) investigate policy implications.

Methods and design

Patients with ESRD who do not have a living kidney donor are eligible to receive the home-based educational intervention. This is carried out by allied-health transplantation professionals and psychologists across 8 hospitals in The Netherlands. The cost-effectiveness analysis will be conducted with a Markov model. Cost data will be obtained from the literature. We will obtain the quality of life data from the patients who participate in the educational programme. Questionnaires on knowledge and communication will be used to measure the outcomes of the programme. Data on LDKT activities will be obtained from medical records up to 24 months after the education. A protocol adherence measure will be assessed by a third party by means of a telephone interview with the patients and the invitees.

Ethics and dissemination

Ethical approval was obtained through all participating hospitals. Results will be disseminated through peer-reviewed publications and scientific presentations. Results of the cost-effectiveness of the educational programme will also be disseminated to the Dutch National Health Care Institute.

Strengths and limitations of this study

- Working with a state-transition model involves a trade-off between feasibility and transparency of the model and the level of details of real life conditions.
- We do not have a control group in the implementation study, we will use the reported effectiveness of a randomized controlled trial conducted previously.
- By making a dynamic state-transition model, we can model the prevalence and incidence of patients with end-stage renal disease, and consequently the capacity for the facility needs which has not been done before.
- We have high quality data at our disposal.

Introduction

Living donor kidney transplantation (LDKT) is the optimal treatment for most patients with end-stage renal disease (ESRD) in terms of Quality Adjusted Life Years (QALYs), survival and cost-effectiveness [1]. However, there is a significant number of patients who cannot find a living kidney donor and many patients first undergo dialysis before transplantation with a living donor kidney. Interventions are needed to improve access to LDKT.

Research has shown that knowledge of renal replacement therapies (RRT) and communication between patients and their social circle play an important role in the access to LDKT [2]. Studies have shown that a home-based interventional programme had positive effects for patients with ESRD [3-5]. In our transplant center in Rotterdam, the Netherlands, we have conducted two studies on this home-based educational approach: one randomized controlled trial (RCT) and one cross-over study. The RCT among 163 patients on dialysis showed significant increases in knowledge and communication about LDKT among the patients in the experimental arm who received the home-based education compared to the standard care control arm. Furthermore, there were significantly more actual LDKTs in the experimental group compared to the control group (17 vs 4, $p=0.003$) [3].

The cross-over trial was aimed at patients who had not previously undergone RRT and who were eligible for transplantation. In the first phase, the experimental arm received the home-based education while the control group waited. In the second phase, the control group also received the education. This study also showed that there was a statistically significant increase

1
2
3 in knowledge and communication regarding RRT among patients and invitees after receiving the
4 home-based education. Of the 80 participants, 49 underwent RRT during the two year follow-up.
5 Of these, 34 underwent a living donor kidney transplantation, of which 22 were pre-emptive [4].
6
7

8 Given these positive results, a home-based educational programme for ESRD patients
9 and their social network is currently being implemented in four regions in The Netherlands. Per
10 region, a regional hospital and a university transplant hospital are implementing the programme.
11 The regional hospitals will target patients who are yet to start renal replacement therapy, while
12 the university hospitals will target both these patients and dialysis patients. The educators
13 organize the intervention in such a way that they will do ‘whatever it takes’, in line with one of
14 the basic principles of multisystem therapy (MST), to make this event as patient-tailored as
15 possible [6]. Supervision and quality assessment are being employed to maintain the quality of
16 the intervention. The first aim of this study is to evaluate the cost-effectiveness of the education
17 to support continued implementation. In this article, we present the study protocol of a cost-
18 effectiveness analysis of the educational programme and its quality assurance system. The
19 patient population, the standard care, the quality of the educations and the setting differ per
20 hospital. Therefore, our second objective is to investigate the relationship between the quality of
21 the implementation of the programme, as measured by protocol adherence, and outcome.
22 Outcome is defined in terms of knowledge, communication, and LDKT activities.
23
24
25
26
27
28
29
30
31
32
33
34
35

36 **Hypotheses**

37 Previous research has provided convincing evidence that transplantation cost less, gives a
38 better survival and a higher quality of life compared to dialysis [7-9]. We therefore hypothesize
39 that the relatively small incremental costs of the home-based educational programme, should be
40 cost-effective. Since it is desirable that in the future all waiting list patients can benefit from the
41 effects of the home-based intervention, this programme should be part of standard care. Hence, a
42 solid basis of the cost-effectiveness of that educational programme is warranted.
43
44
45
46
47

48 The second hypothesis is that higher protocol adherence among healthcare providers will
49 be associated with more positive effects of the educational interventions. These effects include
50 an increase in knowledge of renal disease and the treatment options, an increase in
51 communication with family/friends about renal replacement therapies, an increase in living
52 kidney donation activities, and an increase in QALYs. If a relationship between protocol
53
54
55
56
57
58
59
60

1
2
3 adherence and effects is shown, a quality assurance system should be an inseparable part of the
4 educational programme.
5

6 The third hypothesis is that a full implementation of the educational programme leads to
7 policy implications regarding care for patients with ESRD. Full implementation may affect the
8 need for dialysis centers and transplantation facilities. By modelling the prevalence we can
9 estimate the need for allocating the health care budget. We aim to present the outcomes of the
10 model in a budget impact analysis (BIA).
11
12
13
14

15 Thus, the main aim of this article is to discuss the protocol of the cost-effectiveness study
16 of the home-based educational programme and of the quality assurance programme which
17 currently being implemented in The Netherlands. Additionally, potential policy implications of
18 our hypotheses are discussed in this article.
19
20
21
22
23

24 **Methods and Design**

25 **Participants and procedure**

26 The implementation study is being conducted in the following regions of the Netherlands:
27 Rotterdam, Amsterdam, Nijmegen and Groningen.
28
29
30

31 The home-based educational programme is currently being implemented in eight
32 hospitals in the Netherlands; four university transplant hospitals and four regional hospitals.
33 Regional hospitals were included to reach those patients who are yet to start renal replacement
34 therapy and in this setting, this is the target population. In these hospitals there is a large dialysis
35 unit but no transplants are conducted. For these hospitals, the inclusion criteria are: ≥ 18 years of
36 age, are eligible for transplantation, and primary RRT required within the coming 12 months. In
37 the regional hospitals allied health professionals carry out the intervention. The four university
38 hospitals incorporate both a dialysis unit and a transplant center, therefore in this setting both
39 patients who are yet to start renal replacement therapy and dialysis patients are the target
40 population. Eligible patients for these hospitals are required to be ≥ 18 years, currently
41 undergoing RRT or required within the coming 12 months and eligible for transplantation. In the
42 university hospitals, allied health professionals are accompanied by psychologists to carry out
43 the intervention. The distinction between the university hospitals and the regional hospitals is in
44 line with the protocols of the aforementioned Cross-over study and the RCT. An estimate of the
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 potential candidates for this implementation is about 50 patients per year per university center
4 and 20 patients per regional hospital. The implementation study will take two years.

5
6 If patients have not been able to find living donor candidates in their social network, they
7 will be asked whether they and their social network wish to receive home-based education from
8 health-care educators. The nephrologist explains to the patients that the educators will provide
9 information about renal diseases, the different types of RRT and their impact on quality of life.
10 Furthermore, the educators can help to discuss the possibilities of living donation within the
11 social network of the patient. If the patient consents to the intervention in consultation with
12 his/her nephrologist, the health-care educators contact the patient to make an appointment for the
13 first home session. Patients are supported in inviting their family/friends to the second
14 educational session. After completion of the programme an evaluation consultation is planned
15 with the nephrologist. The number of patients who do not consent to participate in the study is
16 recorded, as well as the reason for nonparticipation.
17
18
19
20
21
22
23
24
25
26

27 **Patient and Public Involvement statement**

28
29 Patients were involved in the design of the educational programme. When designing the
30 intervention we anchored the patient participation in the project approach by relying on the
31 results of focus groups among fifty patients from the intended target group. Their opinion was
32 sought regarding two methods described in the literature of additional information/coaching: 1)
33 an additional telephone consultation by the transplant doctor [10] and 2) home education where
34 family and friends are invited to receive knowledge about RRT. Eighty-eight percent of the
35 participants favoured the home-based education over the telephone consultations [11].
36 Additionally, a patient panel and organizations were involved in the development of the
37 educational programme protocol and materials. Patients were not involved in the design of the
38 cost-effectiveness study.
39
40
41
42
43
44
45
46
47

48 **The intervention: home-based education**

49
50 The intervention consists of two sessions at the patient's home. The intervention is
51 carried out by allied-health transplantation professionals and psychologists. In the first session
52 the goals of the educational programme are discussed and the home-based educational meeting
53 will be prepared. The educators will make an inventory of individuals in the patient's social
54
55
56
57
58
59
60

1
2
3 network using a socio-gram. This helps open the discussion on who to invite for the second
4 session, the home-based educational meeting. The need for an independent translator is also
5 dicussed.
6
7

8 In the second session the education takes place. The educators organize this session in
9 such a way that they will do ‘whatever it takes’, in line with one of the basic principles of
10 multisystem therapy (MST), to make this event as patient-tailored as possible [6]. The primary
11 goal of this intervention is educational, therefore, it is not necessary that all the invitees are or
12 become potential donors. The intervention is based on the previous RCT and Cross-Over studies
13 [3, 4]. A more detailed description can be found in a published protocol manuscript [12].
14
15
16
17
18
19

20 **Measures**

21
22 *Knowledge and communication* are evaluated through questionnaires among all patients
23 and for at least one relative/friend in attendance at the home-based educational session. The
24 knowledge about renal disease and renal replacement therapies is measured through a validated
25 knowledge questionnaire R3K-T. This 21-item knowledge questionnaire has been developed
26 specifically for kidney disease, and has good psychometric properties [13]. Answer categories
27 are multiple choice and the number of correct answers are summed. The 3-item communication
28 questionnaire can be answered on a scale from 1 (completely disagree) to 5 (completely agree).
29 An example item is ‘I can talk about renal replacement therapies with my loved ones’. Finally
30 we assess patients’ and invitees’ attitude towards RRT through a 9-item questionnaire. This
31 questionnaire can also be answered on a scale from 1 (completely disagree) to 5 (completely
32 agree). An item example is ‘I am afraid donation will harm the health of the donor’. The
33 administration of questionnaires will take place at two occasions 1) prior to the education either
34 during an outpatient visit after signing the ‘informed consent form’ or during the first session;
35 and 2) shortly after the second session.
36
37
38
39
40
41
42
43
44
45

46 *Protocol adherence measures:* After every completed home intervention an independent
47 telephone evaluation is conducted with the patient and a relative/friend who attended the
48 education programme, to measure the degree of protocol adherence of the educators. The
49 independence is guaranteed through an independent party, specialized in treatment adherence
50 measurement (www.Praktikon.nl). Protocol adherence in this implementation is defined as the
51 extent to which the different teams carry out the educational programme as described in the
52
53
54
55
56
57
58
59
60

1
2
3 protocol. Measurement is done with an adaptation of the ‘Treatment Adherence Measures’
4 (TAM) questionnaire [14]. TAM is scored on a 0-1 scale, where 1 stands for complete protocol
5 adherence. The results of the TAM can not only be used for research purposes, but also to give
6 the educators feedback on the quality of their interventions during the implementation phase.
7
8
9

10 11 12 **Cost-Effectiveness**

13 *Costs:* The latest published research on costs of dialysis and transplantation in The
14 Netherlands dates back from the late 1990s [7]. Currently, research on costs of dialysis and
15 transplantation is in its final phase. We will use this forthcoming data (De Wit, personal
16 communication). This cost data is of high quality, as it is based on the national database of
17 insurance companies from 2014, which consists of records from 99% of all Dutch citizens. Costs
18 calculations will include costs of dialysis modality, dialysis access, transplant procedure, other
19 hospital costs, primary care costs, mental health care, medication outside the hospital, medical
20 devices, health care abroad, transport, and other costs. Health care costs for transplantation,
21 include preparatory research, transplant operation, guidance, after care, donor expenses, dialysis
22 procedure, other hospital costs, primary care, mental health care, medication outside hospital,
23 medical devices, health care abroad, transportation and other costs. These include all the health
24 care costs associated with RRT. Since it is recommended that cost-effectiveness analysis are
25 conducted from a societal perspective, we also aim to calculate the productivity costs [15].
26 Productivity costs will be estimated with the friction-cost method, as recommended in the Dutch
27 guidelines for economic evaluation [16]. Besides that the work situation of patients participating
28 in the study is recorded, some research has been done regarding labor participation of patients
29 with ESRD [17, 18]. The costs of the home-based intervention and the quality assurance will be
30 estimated on the basis of the current practice in the implementation. Informal care costs will be
31 estimated from the literature [19]. The costs of the intervention are recorded per center.
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 *Effects:* In health economics the effects of interventions under evaluation are preferably
47 expressed in QALYs [15]. Research on QALYs of different dialysis modalities are widespread
48 [8, 20, 21], but instruments and patient background variables vary. Therefore, we are currently in
49 the process of collecting quality of life data from both patients who are yet to start renal
50 replacement therapy and dialysis patients prior to the intervention, through the EQ-5D-5L, the
51 quality of life instrument recommended in the Dutch guidelines for health economics [16]. We
52
53
54
55
56
57
58
59
60

1
2
3 also collect quality of life data from patients after the intervention. The educators administer the
4 EQ-5D-5L questionnaire to patients at baseline, 6, 12 and 24 months after the intervention by
5 telephone.
6
7

8 *Markov Model:* To assess the cost-effectiveness of the implementation of the home-based
9 educational programme, we will build a 'Markov simulation model'. This model will assess the
10 costs and effects of ESRD treatments as it simulates the course of treatment and disease of the
11 patients. The model will have a similar structure as a previously published model on this
12 population [7], with some important updates and improvements. Unlike that Markov model,
13 which used multivariate and univariate sensitivity analyses [7], our model will include
14 probabilistic sensitivity analysis using Monte Carlo simulation. Consequently, uncertainty of all
15 values are considered simultaneously, and the uncertainty in each parameter is assumed to
16 possess a probability distribution [22]. The model will run 10,000 simulations in Microsoft
17 Excel, version 2010. By using probabilistic sensitivity analyses we follow current guidelines in
18 health economics [16, 23, 24]. A Markov modelling technique is applicable because the decision
19 problem involves risk that is continuous over time, the timing of events is important, and events
20 may happen more than once [25]. Within a Markov simulation, the time horizon of the study is
21 divided into a number of discrete time-periods, the so-called Markov cycles. A Markov process
22 is based on the idea that patients are always in a certain disease state and that they can change
23 between disease states once during each cycle. By assigning effects to each disease state and
24 keeping track of the time patients remained in each disease state, long-term effects can be
25 calculated. For this cost-effectiveness analysis the effects and cost per health state do not change
26 because of the intervention. We expect that there will be more LDKTs because of the
27 intervention. Therefore, besides the costs of the programme, only the transition probabilities will
28 change because of the intervention and will be the only difference between the baseline and the
29 post-implementation situation. Table 1 shows an overview of the parameters used and the source.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: overview of parameters and sources in the Markov Model:

Parameter	Sources
Costs	
1. Medical Costs	1. Costs study of RRT in The Netherlands by de Wit et al. (Forthcoming)
2. Intervention Costs	2. Are recorded in the current implementation study
3. Costs of Productivity Losses	3. Work situation of patients is recorded in the implementation study and use of (Dutch) literature [16, 17]
4. Informal Care Costs	4. Will be estimated from existing literature [18].
Effects (QALYs)	EQ-5D-5L are conducted prior at the intervention and 6, 12 and 24 months after the intervention.
Transition probabilities	Estimated from the database of Nefrovisie
1. Between treatment modalities	
2. Mortality rate	
Incidence rates	Estimated from the database of Nefrovisie
Effect size of the intervention	Used from previous studies [3, 4]

Model description: A simplified graphical representation of the Markov model showing only the treatment categories, rather than all the individual Markov states is represented in figure 1. Patients continuously enter the model (inflow) at the start of the cycle and can start on Hemodialysis, Peritoneal dialysis, or Transplantation. From there they can move between these treatment modalities. Diabetics and non-diabetics are modeled separately since the transition probabilities between the treatment modalities differ between these groups. Since the incidence of kidney failure is increasing, we will also model this in the cost-effectiveness analysis. This will be calculated using data from the database of *Nefrovisie*, a large national database with records of ESRD patients. As stated before, the model will include probabilistic sensitivity analysis using Monte Carlo simulation. This means that not only mean numbers of patients per year per treatment modality will be modeled, but also the uncertainty surrounding those mean number of patients, (i.e. 95% confidence intervals). Transition probabilities and incidence rates will be based on primary data and will include uncertainty. Costs and utilities will be included in the model as distributions rather than point estimates.

Markov States: The Markov states are based on the treatments currently available in The Netherlands. These are: full care centre hemodialysis, limited care centre hemodialysis, home hemodialysis, continuous ambulatory peritoneal dialysis, continuous cyclic peritoneal dialysis, deceased donor kidney transplantation, and living donor kidney transplantation. Since transition

1
2
3 probabilities and costs may differ over time, i.e. a patient who is in his second year of
4 hemodialysis has a different mortality chance than a patient who just started with hemodialysis,
5 we will define separate Markov states for the 1st year of treatment and subsequent years of
6 treatment for each specific modality. Incident patients that enter the model and prevalent patients
7 that switch between treatment modalities are assigned to the 1st year Markov states, whereas
8 patients that spend more than one year in any health state are transferred to the subsequent years
9 of that same treatment modality.

10
11
12
13
14
15 *Outcomes:* The outcome of the implementation will be compared with the baseline
16 situation; the situation before this programme was implemented. The effect size, in terms of an
17 increase in LDKT, will be used from the RCT conducted earlier. Through sensitivity analyses an
18 estimation can be made of the cost-effectiveness of the intervention whether this assumption is
19 either an under- or overestimation. A critical assumption will be the extrapolation of the effects
20 after the 2 years.

21 22 23 24 25 26 27 **Quality Assurance**

28
29 This study has also implemented a central quality assurance system. We hypothesize that
30 the effectiveness is moderated by the protocol adherence of the team of healthcare professionals.
31 In the implementation study, it might be possible that there are differences in the way teams and
32 centers adhere to the protocol. Protocol adherence measures will be assessed by a third party by
33 means of a telephone interview with the patients and the invitees. Patients and invitees are asked
34 for their opinion and level of satisfaction regarding the way in which the intervention was
35 delivered. Patients and invitees are asked to answer the 15-item TAM-scoring list. Items are
36 rated on a Likert-scale (1 not at all – 5 very much). Only items that are rated with a 5, will be
37 regarded as fully adherent. Items scored with a 1-4 will be regarded as non-adherent. The
38 outcome of the protocol adherence will be associated with the gain in knowledge and
39 communication skills. We will also look if there is a correlation between the protocol adherence
40 and the amount of LDKTs. A part of the quality assurance is a training that all professionals who
41 conduct the home interventions must take part in. During this training, issues are discussed such
42 as: how to convey uniform and complete information to the patient, how to behave during the
43 home visits, how to create an alignment of the goals of the home visit with the patients, how to
44 assist the patient in inviting friends and relatives, how to deal with emotional moments, how to
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 discuss delicate topics with respect to individual feelings and opinions and finally, how to ensure
4 no detrimental psychosocial effects of the education occur for the patients and his/her
5 family/friends. All these aspects can be executed in different ways by the educators. A supervisor
6 evaluates the home visits with each team separately every six weeks and discuss difficult cases.
7
8 After these meetings the supervisor is graded by the educators through a 10-item questionnaire
9 regarding the content of the teaching and the interpersonal delivery of the supervisor.
10
11 Furthermore, the supervisor will bring together all educators for a so-called intervision meeting
12 every three months. These intervision sessions are meant to discuss the home visits with each
13 other in order to learn from each other and to keep the procedures similar.
14
15
16
17
18
19
20
21

22 Discussion

23
24 We presented a protocol for assessing the cost-effectiveness of our home-based
25 educational programme and its generalizability. The implementation of the educational
26 programme might both benefit patients and society.
27
28

29 *Cost-effectiveness:* If indeed our hypotheses are confirmed, and the home-based
30 educational programme is cost-effective, then there are convincing arguments to make the
31 programme standard care in The Netherlands. Health insurers already expressed their interest in
32 the programme; this implementation study is supported by *Zorgverzekeraars Nederland* (Health
33 insurers The Netherlands), which is the ‘umbrella organization’ of all health insurers in The
34 Netherlands. Additionally, the Dutch Kidney Foundation supports the programme and
35 contributed through three grants in the developmental phases of the home-based educational
36 programme. The Dutch Kidney Foundation is a non-profit organization which subsidizes
37 research and innovation in nephrology and renal transplantation care. Indeed, the health
38 insurance companies have good reason to be interested, as dialysis is costly. In The Netherlands,
39 1% of the total healthcare budget is spent on ESRD patients, who only constitute 0.0006% of the
40 population [26, 27]. Furthermore, transplantation is associated with higher quality of life for
41 ESRD patients compared to dialysis treatment. It is therefore valuable, from both patient and
42 societal perspective, to conduct a complete and extensive cost-effective analysis and
43 consequently to follow up those results in terms of policy.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Quality Assurance System: Protocol adherence may be of importance to guarantee the effects of the home-based education. First, we expect a positive relation of adherence with outcome in terms of communication, knowledge and the number of transplantations. Second, any problems or regrets of donors and/or patients can only be justified if the evidence based protocol was followed. The protocol has also been developed after thorough ethical consideration (23), which justified all characteristics of the programme. It can therefore be argued that health insurance make reimbursement indispensable of the degree of protocol adherence of healthcare suppliers. Moreover, they should facilitate the quality assurance system as an integral part of the programme and ensure that the quality of the interventions is independent of the healthcare suppliers.

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Limitations: Investigating the (cost-)effectiveness of the home-based educational programme has its limitations. In health economic modelling, there is always a trade-off between the feasibility and transparency of the cost-effectiveness model and the level of details of real life conditions as represented in the model. The more details, the more the model resembles real life, but the down side is that data should be available at that same level of detail and that the model becomes too complex in its feasibility. An example is that we assume that the mortality on dialysis is the same in the second and following years on dialysis. Hence, we know from literature that the mortality chance changes, but the data in later years is scarce and again the model would become more complex, as more ‘tunnels states’ have to be introduced. We expect that this trade-off will be most prominent in the transition changes between health states. We expect less obvious trade-offs for costs and utility assessment, as we have sufficient data for those variables.

41
42
43
44
45
46
47
48
49
Cooperation. This investigation is a cooperation between many parties, who all have expressed their support. Obviously, it is possible that this support can be withdrawn for several reasons. For instance, we depend on data from a large national database with records of patient with ESRD (*Nefrovisie*). Hence, much efforts are and will be put in preserving relationships and communication in order to maximize fair successful implementation chances for the programme.

50
51
52
53
54
55
56
57
Ethical considerations. Another challenge that we face, is the ethical consideration of promoting living kidney donation through a home-based intervention. Previous studies on the ethics of this argued that such promotion is justified, only when the conditions are met, such as 1) participation must be completely voluntary throughout the intervention, 2) no undue pressure

1
2
3 should be put on the participants, 3) the education is neutral and non-directive and 4) the purpose
4 and the procedure should be clear to all participants [28, 29]. That does not mean there are no
5 negative consequence whatsoever, but it does mean that the positive outcomes outweigh the
6 negative. It could well be that a patient and/or a donor may regret the decision to have
7 undertaken a transplantation with a kidney of a living donor, and that the donor and/or patient, in
8 hindsight, may have felt undue pressure to donate a kidney. Adherence to the protocol will
9 minimize these potential negative effects. However, it is possible that regret or pressure could
10 lead to negative publicity for the programme. That is a risk since such negative publicity could
11 impede the chances of implementing the programme as standard care [30]. Especially
12 considering that deceased organ donation is currently subject to controversy in The Netherlands
13 since the government and parliament have accepted a donor law. This law is an opt-out system
14 entailing a positive 'no-objection' deceased donor organ donor registration as a default for all
15 Dutch citizens [31]. Given this potential harm due to negative publicity it is crucial to have 1) a
16 protocol which is justifiable from a medical ethical perspective, 2) widespread support from the
17 various organizations involved and 3) a high quality in terms of protocol adherence and trained
18 adequate educators. If these conditions are met, the quality of the process then justify its
19 outcome, which is a subtle trade-off between positive and negative outcomes.

20
21
22
23
24
25
26
27
28
29
30
31
32
33 *Implementation.* Another challenge is the generalizability of the results of the previous
34 effect study on home-based interventions done in Rotterdam. The randomized controlled trial in
35 the Rotterdam transplant area has shown that the home-based educational programme leads up to
36 four times more LDKTs. The trial took place at the academic transplant center (Erasmus Medical
37 Center in Rotterdam) where extensive efforts were already undertaken as part of the standard
38 care to promote LDKTs [3, 32]. It is possible that in other transplant areas in The Netherlands,
39 with less experience regarding promoting LDKT, effectiveness in terms of amount of LDKTs
40 may differ. On one hand this more cautious attitude may lead to lower results than in the
41 Rotterdam transplant area. Hence, organizational conditions within those transplant centers may
42 not optimally facilitate the favorable results of the interventions. On the other hand, if the
43 number of LDKT was lower than in the Rotterdam area, and the uptake of the intervention is
44 high, the effect could even be higher than in the Rotterdam area. This is due to a higher effect
45 potential in those centers where living donation was not promoted as actively.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 *Learning curve.* As with all new programmes, educators will inherently experience a
4 learning curve during the first part of the implementation, which could influence the
5 effectiveness of the programme. For instance, the goal of 50 patients per year per academic
6 transplant center and the goal of 20 patients per regional hospital may not be reached. Regular
7 supervision, (on the job) training and peer-to-peer coaching may help to overcome this, but a
8 learning curve is unavoidable.
9

10
11 *Policy implications:* One of the main pillars of an efficient health care system is the
12 ability to provide effective care to patients when needed. It is therefore necessary to have
13 information on the effectiveness of the interventions and their cost to convince policy makers to
14 reimburse the treatment. If the analysis confirms the effectiveness as well as the cost-
15 effectiveness of the home-based educational programme, we recommend that this intervention
16 should be part of standard-care.
17
18

19
20 If the home-based educational interventions would become standard-care, this could have
21 several implications. First, it can be expected that patients who are unable to find a living donor
22 will nevertheless profit from an increase number of living kidney donations, as the demand for
23 deceased donor kidneys drops. In other words, the increase in living donation will further lower
24 the waiting list for deceased donor donation as well and thereby increase the chance of a
25 deceased donor donation for those patients without a living donor increases.
26
27

28
29 Second, the composition of the population of patients with ESRD may change. For
30 instance, it can be expected that the proportion of patients on dialysis will drop and patients with
31 a life sustaining transplanted kidney will increase. This might have an influence on the demand
32 for dialysis centers and the need for transplantation facilities. We, therefore, aim to incorporate
33 this in a so-called dynamic model to estimate the prevalence over time. When modelling the
34 prevalence, we could make estimates of the need for dialysis centers and transplantations
35 facilities. However, modelling the facility is surrounded by uncertainty. For instance, dialysis
36 centers may have financial incentives to fulfill dialysis capacity. If this would be the case, there
37 will be no monetary benefits for society by increasing the transplants facilities if the proportion
38 of dialysis capacity remains the same. This would mean that there will only be an increase in the
39 average quality of life of ESRD-patients.
40
41

42
43 Finally, a cost-effectiveness analysis only might not be sufficient to set policy change in
44 motion. Therefore, we anticipate that a policy recommendation accompanied with a BIA will
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 also be required. A BIA addresses the expected changes in the expenditure of a health care
4 system after the adoption of a new intervention. It can also be used for budget and resource
5 planning [33, 34].
6
7

8 *Conclusion:* If our hypotheses are confirmed, we hope by presenting an extensive cost-
9 effectiveness analysis, a BIA, and a policy recommendation that policy change will be set in
10 motion, which again would benefit both ESRD-patients and society.
11
12
13
14
15
16
17
18
19
20

21 **Declarations**

22 **Abbreviations**

23 BIA: Budget Impact Analysis; ESRD: End-Stage Renal Disease; LDKT: Living Donor Kidney
24 Transplantation; RCT: Randomized Controlled Trial; RRT: Renal Replacement Therapies; QALY:
25 Quality Adjusted Life Years; TAM; Treatment Adherence Measures.
26

27 **Acknowledgements**

28 All authors express their gratitude to the participating hospitals, the educators and their supervisors.
29
30

31 **Funding**

32 The research is funded by the Dutch Kidney Foundation (Nierstichting). The implementation is supported
33 by Dutch Health Insurers (Zorgverzekeraars Nederland).
34

35 **Availability of data and materials**

36 Not applicable.
37
38

39 **Author contributions**

40 SR drafted the manuscript. MO, MV, JB, WW, EM, SI provided significant critical intellectual
41 contributions. All authors reviewed and approved the final version of this manuscript and agrees to be
42 accountable for all aspects of this work.
43
44

45 **Consent for publication**

46 Not applicable.
47
48

49 **Competing interests**

50 All authors have no competing interests to report.
51
52
53
54
55
56
57
58
59
60

Ethics and dissemination

Ethical approval is obtained through all participating hospitals. Results will be disseminated through peer-reviewed publications and scientific presentations. Results of the cost-effectiveness of the educational programme will also be disseminated to the Dutch National Health Care Institute.

References

1. Mahillo B, Carmona M, Alvarez M, White S, Noel L, Matesanz R: **2009 global data in organ donation and transplantation: activities, laws, and organization.** *Transplantation* 2011, **92**(10):1069-1074.
2. Kranenburg LW, Zuidema WC, Weimar W, Hilhorst MT, IJzermans JN, Passchier J, Busschbach JJ: **Psychological barriers for living kidney donation: how to inform the potential donors.** *Transplantation* 2007, **84**:965-971.
3. Ismail SY, Luchtenburg AE, Timman R, Zuidema WC, Boonstra C, Weimar W, Busschbach JJ, Massey EK: **Home-based family intervention increases**

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- knowledge, communication and living donation rates: a randomized controlled trial.** *Am J Transplant* 2014, **14**(8).
4. Massey EK, Gregoor PJ, Nette RW, van den Dorpel MA, van Kooij A, Zietse R, Zuidema WC, Timman R, Busschbach JJ, Weimar W: **Early home-based group education to support informed decision-making among patients with end-stage renal disease: a multi-centre randomized controlled trial.** *Nephrol Dial Transplant* 2016, **31**(5):823-830.
5. Rodrigue JR, Cornell DL, Lin JK, Kaplan B, Howard RJ: **Increasing live donor kidney transplantation: a randomized controlled trial of a home-based educational intervention.** *Am J Transplant* 2007, **7**(2):394-401.
6. Henggeler SW, Schoenwald SK, Borduin CM, Rowland MD, Cunningham PB: **Multisystemic Therapy for Antisocial Behavior in Children and Adolescents.** New York: The Guilford Press; 2009.
7. de Wit GA, H. RP, de Charro FT: **Economic evaluation of end stage renal disease treatment.** *Health policy* 1998, **44**(3):215-232.
8. Wyld M, Morton RL, Hayen A, Howard K, Webster AC: **A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments.** *PLoS Med* 2012, **9**(9):e1001307.
9. Liem YS, Bosch JL, Hunink MG: **Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis.** *Value Health* 2008, **11**(4):733-741.
10. Hartmann A: **Managing a living donor program: the Oslo experience.** Presented at the 11th Conference of the European Society of Organ Transplantation. Venice. Septemeber 20-24, 2003
11. Ismail SY, Claassens L, Luchtenburg AE, Roodnat JJ, Zuidema WC, Weimar W, Busschbach JJ, Massey EK: **Living donor kidney transplantation among ethnic minorities in the Netherlands: a model for breaking the hurdles.** *Patient Educ Couns* 2013, **90**(1):118-124.
12. Ismail SY, Luchtenburg AE, Zuidema WC, Boonstra C, Weimar W, Massey EK, Busschbach JJ: **Multisystemic engagement & nephrology based educational intervention: a randomized controlled trial protocol on the kidney team at home-study.** *BMC Nephrology* 2012, **13**:62-70.
13. Ismail SY, Timmerman L, Timman R, Luchtenburg AE, Smak Gregoor PJH, Nette RW, van den Dorpel MA, Zuidema WC, Weimar W, Massey EK *et al*: **A psychometric analysis of Rotterdam Renal Replacement Knowledge-Test (R3K-T) using item response theory.** *Transplant International* 2013, **26**:1164-1172.
14. Chapman JE, Sheidow AJ, Henggeler SW, Halliday-Boykins C, Cunningham PB: **Developing a Measure of Therapist Adherence to Contingency Management: An Application of the Many-Facet Rasch Model.** *J Child Adolesc Subst Abuse* 2008, **17**(3):47-68.


15. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW: **Methods for the Economic Evaluation of Health Care Programmes**. Oxford: Oxford University; 2015.
16. Zorginstituut Nederland: **Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg**. In. Diemen: Nederland Zorginstituut 2015.
17. Kuiper D, Brouwer S, Groothogg J, van der Mei S: **Arbeidsparticipatie na niertransplantatie: een prospectieve studie**. In. Groningen: Rijksuniversiteit Groningen; 2009.
18. Jarl J, Gerdtham UG, Desatnik P, Prutz KG: **Effects of Kidney Transplantation on Labor Market Outcomes in Sweden**. *Transplantation* 2018, **102**(8):1375-1381.
19. Hoang VL, Green T, Bonner A: **Informal caregivers' experiences of caring for people receiving dialysis: A mixed-methods systematic review**. *J Ren Care* 2018, **44**(2):82-95.
20. Harris A, Cooper BA, Li JJ, Bulfone L, Branley P, Collins JF, Craig JC, Fraenkel MB, Johnson DW, Kesselhut J *et al*: **Cost-effectiveness of initiating dialysis early: a randomized controlled trial**. *Am J Kidney Dis* 2011, **57**(5):707-715.
21. Wu AW, Fink NE, Marsh-Manzi JV, Meyer KB, Finkelstein FO, Chapman MM, Powe NR: **Changes in quality of life during hemodialysis and peritoneal dialysis treatment: generic and disease specific measures**. *J Am Soc Nephrol* 2004, **15**(3):743-753.
22. Doubilet P, Begg CB, Weinstein MC, Braun P, J. MB: **Probabilistic Sensitivity Analysis Using Monte Carlo Simulation**. *Med Decis Making* 1985, **5**(2):157-177.
23. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ: **Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophage reflux disease**. *Med Decis Making* 2002, **22**:290-308.
24. Briggs AH: **Handling uncertainty in cost-effectiveness models**. *Pharmacoeconomics* 2000, **17**(5):479-500.
25. Sonnenberg FA, Beck JR: **Markov Models in Medical Decision Making: A Practical Guide**. *Med Decis Making* 1993, **13**:322-338.
26. **Ranglijst ziekten op basis van zorgkosten**
[\[https://www.volksgezondheidenzorg.info/ranglijst/ranglijst-ziekten-op-basis-van-zorgkosten\]](https://www.volksgezondheidenzorg.info/ranglijst/ranglijst-ziekten-op-basis-van-zorgkosten)
27. **Feiten en cijfers over behandeling nierfalen**
[\[https://www.nierstichting.nl/leven-met-een-nierziekte/feiten-en-cijfers/\]](https://www.nierstichting.nl/leven-met-een-nierziekte/feiten-en-cijfers/)
28. Hilhorst MT, Kranenburg LW, Busschbach JJ: **Should health care professionals encourage living kidney donation**. *Medicine, Health Care and Philosophy* 2006, **10**:81-90.
29. Massey EK, Hilhorst MT, Nette RW, Smak Gregoor PJH, van den Dorpel MA, van Kooij A, Zuidema WC, Zietse R, Busschbach JJ, Weimar W: **Justification**

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
- for a home-based education programme for kidney patients and their social network prior to initiation of renal replacement therapy. *J Med Ethics* 2011, **37**:677-681.
30. Birkland TA: **Focusing Events, Mobilization, and Agenda Setting.** *Journal of Public Policy* 1998, **18**(1):53-74.
31. Eleftheriou-Smith L: **Organ Donation set to become automatic for Dutch people unless they opt out.** In: *Independent*. 2016.
32. Roodnat JJ, Kal-V Gestel JA, Zuidema WC, van Noord MAA, van de Wetering J, IJzermans JN, Weimar W: **Successful Expansion of the Living Donor Pool by Alternative Living Donation Programs.** *Am J Transplant* 2009, **9**(9):2150-2156.
33. Niezen MG, de Bont A, Busschbach JJ, Cohen JP, Stolk EA: **Finding legitimacy for the role of budget impact in drug reimbursement decisions.** *Int J Technol Assess Health Care* 2009, **25**(1):49-55.
34. Sullivan SD, Mauskopf JA, Augustovski F, Caro JJ, Lee KM, Minchin M, Orlewska E, Penna P, Rodriguez Barrios J-M, Wen-Yi S: **Budget Impact Analysis - Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.** *Value in Health* 2014, **17**:5-14.
- 31

Figure legends

32 Figure 1: A simplified graphic representation of the Markov Model with the different
33 health states and the transition possibilities between the health states.
34

35
36
37 Table 1: overview of parameters and sources in the Markov Model.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



A simplified graphic representation of the Markov Model with the different health states and the transition possibilities between the health states.

234x151mm (300 x 300 DPI)